Amgen AMGN · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
S&P 500Nasdaq-100Dow Jones
465.23
+1.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Amgen
From its filings with the US Securities and Exchange Commission
Amgen is based in Thousand Oaks, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AMGN. It is a member of the S&P 500, Nasdaq-100 and Dow Jones. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $36.75bn and net income of $7.71bn. At that date it held total assets of $90.59bn and shareholders' equity of $8.66bn. By region, U.S. accounted for 71.9%, followed by ROW at 28.1%.
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development. We have a presence in approximately 100 countries worldwide.
Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen operates in one operating segment: human therapeutics.
Following is a summary of significant developments affecting our business that have occurred and that we have reported since the filing of our Annual Report on Form 10-K for the year ended December 31, 2024.
In August 2025, we announced that the FDA broadened the approved use of Repatha to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), removing the previous requirement that a patient have been diagnosed with cardiovascular (CV) disease.
Quoted from its 10-K, filed 13 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 May 1987
- Employees
- 31,500
- Website
- amgen.com ↗
- Head office
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Robert BradwayChairman of the Board, President, Chief Executive Officer, since 2007$24.4m
- Mr. Peter GriffithChief Financial Officer, Executive Vice President$7.8m
- Dr. David ReeseExecutive Vice President, Chief Technology Officer$8.1m
- Dr. James BradnerExecutive Vice President - Research and Development and Chief Scientific Officer$14.9m
- Mr. Jonathan GrahamExecutive Vice President, General Counsel, Secretary$7.2m
- Mr. Murdo GordonExecutive Vice President - Global Commercial Operations$8.5m
- Mr. Esteban SantosExecutive Vice President - Operations$7.2m
- Ms. Nancy GrygielSenior Vice President, Chief Compliance Officer
- Mr. Derek MillerSenior Vice President - Human Resources
- Ms. Rachna KhoslaSenior Vice President - Business Development
- Mr. Robert EckertLead Independent Director$450,067
- Dr. Wanda AustinIndependent Director$370,183
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 89
- Social
- 99
- Governance
- 67
- Direct emissions (scope 1)
- 147,000 t
- Energy emissions (scope 2)
- 128,000 t
- Value chain emissions (scope 3)
- 1,705,000 t
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Amgen Inc. possesses several strengths that contribute to its success in the biotechnology industry. These strengths include:
Weaknesses
- Despite its strengths, Amgen Inc. also faces certain weaknesses that may pose challenges to its growth and competitiveness:
Opportunities
- Amgen Inc. can capitalize on various opportunities in the biotechnology market to further enhance its position and drive growth:
Threats
- Amgen Inc. must also navigate several threats that could negatively impact its operations and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.